Immunomodulator therapy: Monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Lee, Susan J ^a,b   Chinen, Javier ^c   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

autoimmunity; cytokines; fusion proteins; immunoglobulins; Monoclonal antibodies

Indexed keywords

ABATACEPT; ABT 874; ADALIMUMAB; ALEFACEPT; ALPHA INTERFERON; BASILIXIMAB; BETA INTERFERON; CERTOLIZUMAB PEGOL; DACLIZUMAB; DRUG ANTIBODY; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 7; METHOTREXATE; NATALIZUMAB; OMALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RILONACEPT; RITUXIMAB; TOCILIZUMAB; USTEKINUMAB;

ADVANCED CANCER; AGAMMAGLOBULINEMIA; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ASEPTIC MENINGITIS; BACKACHE; BEHAVIOR; BILIRUBIN BLOOD LEVEL; BIOTECHNOLOGY; CELL ADHESION; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CROHN DISEASE; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DERMATOMYOSITIS; DOSE RESPONSE; DRUG BINDING; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; ENDOCRINE OPHTHALMOPATHY; FEEDBACK SYSTEM; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL INFECTION; GLYCOSYLATION; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INFECTION; INFECTION RISK; INFECTION SENSITIVITY; INFLAMMATION; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CANCER; KIDNEY DISEASE; LIVER FUNCTION TEST; LUNG EDEMA; LYMPHOCYTE DIFFERENTIATION; MELANOMA; METASTASIS; MOLECULAR INTERACTION; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; MYELITIS; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PARESTHESIA; PARVOVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SJOEGREN SYNDROME; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOSIS; TISSUE REPAIR; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION; URTICARIA; UVEITIS; VASCULITIS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CELL MIGRATION INHIBITION; CYTOKINES; DRUG DISCOVERY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 76749136238     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.08.018     Document Type: Article

References (69)

1. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
2. Lipsky P.E., van der Heijde D.M., St Claire E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
3. Moreland L.W., Weinblatt M.E., Keystone E.C., Kremer J.M., Martin R.W., Schiff M.H., et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33 (2005) 854-861
4. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54 (2006) 76-81
5. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. [published erratum appears in Arthritis Rheum 2003;48:855]. Arthritis Rheum 48 (2003) 35-45
6. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid arthritis). J Rheumatol 30 (2003) 2563-2571
7. Kay J., Matteson E.L., Dasgupta B., Nash P., Durez P., Hall S., et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 58 (2008) 964-975
8. Keystone E., van der Heijde D., Mason Jr. D., Landewe R., van Vollenhoven R., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis Rheum 58 (2008) 3319-3329
9. St Clair E.W., van der Heijde D.M.F.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 50 (2004) 3432-3443
10. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two year radiographic and clinical outcomes. Arthritis Rheum 46 (2002) 1443-1450
11. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
12. Landewe R., van der Heijde D., Klareskog L., van Vollenhoven R., and Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 54 (2006) 3119-3125
13. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359 (2008) 810-820
14. Ruperto N., Lovell D.J., Cuttica R., Wilkinson N., Woo P., Espada G., et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 59 (2007) 3096-3106
15. Antoni C.E., Kavanaugh A., van der Heijde D., Beutler A., Keenan G., Zhou B., et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 35 (2008) 869-876
16. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
17. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: result of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
18. Rozenblit M., and Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 22 (2009) 56-60
19. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52 (2005) 582-591
20. Baraliakos X., Brandt J., Listing J., Haibel H., Sörensen H., Rudwaleit M., et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53 (2005) 856-863
21. Sieper J., Baraliakos X., Listing J., Brandt J., Haibel H., Rudwaleit M., et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumor necrosis factor agent infliximab. Rheumatology 44 (2005) 1525-1530
22. Van der Heijde D., Landewe R., Baraliakos X., Houben H., van Tubergen A., Williamson P., et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58 (2008) 3063-3070
23. van der Heijde D., Pangan A.L., Schiff M.H., Braun J., Borofsky M., Torre J., et al. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67 (2008) 1218-1221
24. Inman R.D., Davis Jr. J.C., Heijde D., Diekman L., Sieper J., Kim S.I., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58 (2008) 3402-3412
25. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
26. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
27. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
28. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
29. Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Eng J Med 357 (2007) 228-238
30. Schreiber S., Khaliq-Kareemi M., Lawrence I.C., Thomsen O.O., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Eng J Med 357 (2007) 239-250
31. Baert F., Noman M., Verneire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
32. Hyrich K.L., Lunt M., Watson K.D., Symmons D.P.M., Silman A.J., and for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 13-20
33. Kapoor D., and Ruderman E.M. Safety of newer therapies in rheumatoid arthritis. Rheum Dis Clin Updates 2 (2007) 1-9
34. Lee S.J., and Kavanaugh A. Adverse events related to biologic agents. J Allergy Clin Immunol 116 (2005) 900-905
35. Ross J.B., Finlayson L.A., Klotz P.J., Langley R.G., Gaudet R., Thompson K., et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 12 (2008) 8-16
36. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndrome. Arthritis Rheum 58 (2008) 2443-2452
37. Smolen J.F., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 371 (2008) 987-997
38. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces diseae activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 58 (2008) 2968-2980
39. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 20008;67:1516-1523.
40. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 66 (2007) 1162-1167
41. Welzel T.M., Morgan T.R., Bonkovsky H.L., Naishadham D., Pfeifer R.M., Wright E.C., et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-alpha 2a plus reibavirin in the treatment of hepatitis C virus infection in the hepatitic C antiviral long-term treatment against cirrhosis trial. Hepatology 49 (2009) 1847-1858
42. Coppin C., Le L., Porzsolt F., and Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev (2008) (2):CD006017
43. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 65 (2009) 499-509
44. Holland S.M. Chronic Granulomatous Disease. Clin Rev Allergy Immunol (2009) [Epub ahead of print]
45. Tarhini A.A., Kirkwood J.M., Gooding W.E., Moschos S., and Agarwala S.S. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer 113 (2008) 1632-1640
46. Mitsuyasu R., Gelman R., Cherng D.W., Landay A., Fahey J., Reichman R., et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial-AIDS Clinical Trials Group 328. Arch Intern Med 167 (2007) 597-605
47. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelièvre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 119 (2009) 997-1007
48. Waldmann T.A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 27 (2007) 1-18
49. Genovese M.C., Schiff M., Luggen M., Becker J.C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67 (2008) 547-554
50. Kremer J.M., Geneant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58 (2008) 953-963
51. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67 (2008) 1096-1103
52. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
53. Sugiyama H., McCormick T.S., Cooper K.D., and Korman N. Alefacept in the treatment of psoriasis. Clin Dermatol 26 (2008) 503-508
54. Krueger G.G., Gottlieb A.B., Sterry W., Korman N., and van de Kerkhof P. A multiceter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatol Treat 19 (2008) 146-155
55. Mease P.J., Gladman D.D., and Keystone E.C. Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis. Arthritis Rheum 54 (2006) 1638-1645
56. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 98 (2003) 1951-1957
57. Krueger G.G., Langley R.G., Leonardi C., Yeilding N., Guzzo C., Wang Y., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
58. Gottlieb A., Menter A., Mendelsohn A., Shen Y.K., Li S., Guzzo C., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet 373 (2009) 633-640
59. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54 (2006) 1390-1400
60. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006) 2793-2806
61. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56 (2007) 3896-3908
62. Calabrese L.H., and Molloy E.S. Progressive multifocal leucoencephalopathy in the rheumatic disease: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67 suppl III (2008) iii64-iii65
63. Slavin R.G., Ferioli C., Tannenbaum S.J., Martin C., Blogg M., and Lowe P.J. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 123 (2009) 107-113
64. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2005) 309-316
65. Hutchinson M., Kappos L., Calabresi P.A., Confavreux C., Giovannoi G., Galetta S.L., et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256 (2009) 405-445
66. Toth D.P., Papp K., and Gratton D. Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. Dermatol Ther 21 suppl 3 (2008) S6-S14
67. Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol 122 (2008) 1038-1039
68. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 suppl (2006) S525-S553
69. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., and Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008) 373-376